UE2343: Clinical Trials

7 trials of UE2343, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 24Completed 3, Active not recruiting 1
Phase 31Active not recruiting 1

Follow UE2343: new trials by email Literature Review of UE2343 trials Research Report on UE2343

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem, Placebo - Dementia Moderate, Dementia, Mild
Phase 2 / Phase 3Active not recruitingActinogen Medical2472024-04-122026-10-21
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem™, Placebo - Major Depressive Disorder, MDD
Phase 2CompletedActinogen Medical1672022-11-282025-01-22
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Xanamem® 5 mg, Placebo, Xanamem® 10 mg - Mild Cognitive Impairment, Alzheimer's Disease
Phase 1 / Phase 2CompletedActinogen Medical1072021-06-302025-01-23
Xanamem™ in Healthy Elderly Subjects
Xanamem, Matching Placebo - Safety, Peripheral Neuropathy
Phase 1CompletedActinogen Medical422019-01-212025-01-22
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Xanamem™, Placebo (for Xanamem™) - Dementia, Alzheimer Type
Phase 2CompletedActinogen Medical1852017-03-232025-02-03
Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects
UE2343, Placebo - Healthy Volunteers
Phase 1CompletedActinogen Medical402015-02-012025-01-22
A Phase I Study of Oral UE2343 in Healthy Subjects
UE2343, Placebo - Healthy
Phase 1CompletedUniversity of Edinburgh482013-01-012013-07-17

Conditions studied

Cognitive Dysfunction (3)  ·  Alzheimer Disease (2)  ·  Dementia (2)  ·  Depressive Disorder, Major (1)  ·  Lymphoma, Follicular (1)  ·  Peripheral Nervous System Diseases (1)  ·  Small Fiber Neuropathy (1)

Sponsors

Actinogen Medical (6)  ·  University of Edinburgh (1)

Countries

Australia (6)  ·  United Kingdom (3)  ·  United States (2)

Top investigators

Bill Ketelbey, MD (2)  ·  Alan Boyd, MD, FFPM (1)  ·  Brian R Walker, BSc MBChB MD (1)  ·  Janakan Krishnarajah (1)  ·  Miriam Roesner (1)  ·  Vincent Ruffles (1)

Results publications

PMID 28012176, PMID 38848180